#161772

OV-2085 cell line

Cat. #161772

OV-2085 cell line

Cat. #: 161772

Organism: Human

Tissue: Derived from ascites of patient with high grade serous carcinoma

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Sauriol A et al. 2020. Cancers. 12(8):2222. PMID: 32784519

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: OV-2085 cell line
  • Alternate name: OV-2085
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from ascites of patient with high grade serous carcinoma
  • Donor: Grade 3 – Stage IIIC;Mutations: TP53; Carboplatin/Taxol
  • Morphology: Homogenous morphology after 60 passages - small clusters of loosely attached round cells growing perpendicularly to culture plate
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Epthelial ovarian cancer cell line derived from high grade serous carcinoma ascites. Cell line produces tumors in mice upon SC injection
  • Production details: Patient ascites were centrifuged and seeded in 100mm plate with OSE medium and maintained for 40 days with weekly media replacement.
  • Additional notes: Patient 2085 had family history of breast cancer, no BRCA mutation, and was age 63 at age of diagnosis. Patient received carboplatin and Paclitaxel prior to sampling. Sampling took place in 2004

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Temperature: 37° C
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin

References

  • Gaia-Oltean et al. 2021. Exp Ther Med. 21(3):243. PMID: 33603851 Canals Hernaez et al. 2020. J Immunother Cancer. 8(2):e001128. PMID: 33243933 Borzdzi?owska et al. 2022. Biomedicines. 11
  • 10(5):1116. PMID: 35625852 Meng et al. 2023. J Anim Sci. 3
  • 101:skad215. PMID: 37351870 Koni et al. 2020. Int J Mol Sci. 18
  • 21(20):7697. PMID: 33080952